| 52.99 Data as of 4:01pm ET |  +0.36 / +0.68%Today’s Change | 33.92 Today|||52-Week Range 55.94 | +11.84% Year-to-Date |
| Encouraging data from Bristol-Myers - Analyst Blog Jun 05 / Zacks.com | Mixed News on Merck's Pipeline - Analyst Blog May 28 / Zacks.com |
| Pipeline Setbacks at Sanofi - Analyst Blog Jun 04 / Zacks.com | Back to Neutral on Hospira - Analyst Blog May 28 / Zacks.com |
| Sanofi Stock Buy Recommendation Reiterated (SNY) Jun 04 / TheStreet.com | Encouraging News for Peregrine Pharma - Analyst Blog May 24 / Zacks.com |
| GSK/Genmab Report Positive Arzerra Data - Analyst Blog May 31 / Zacks.com | Encouraging News for Peregrine Pharma - Analyst Blog May 23 / Zacks.com |
| Medivation/Astellas Seek Xtandi Approval in Japan - Analyst Blog May 29 / Zacks.com |
| Previous close | 52.63 |
| Today’s open | 52.58 |
| Day’s range | 52.37 - 53.19 |
| Volume | 2,648,362 |
| Average volume (3 months) | 2,411,343 |
| Market cap | $139.3B |
| Dividend yield | 3.38% |
| Earnings growth (last year) | -19.51% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +7.12% |
| Revenue growth (last year) | -3.43% |
| P/E ratio | -- |
| Price/Sales | 2.77 |
| Price/Book | 1.84 |
| Today’s change | Today’s % change | |
|---|---|---|
| MRKMerck & Co Inc | -0.13 | -0.27% |
| GSKGlaxoSmithKline PLC | +0.58 | +1.15% |
| NVSNovartis AG | +0.39 | +0.55% |
| PFEPfizer Inc | +0.63 | +2.29% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | $0.90 |
| Annual revenue (last year) | $45.1B |
| Annual profit (last year) | $6.4B |
| Net profit margin | 14.21% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Christopher A. Viehbacher, CPA |
President- Global Operations Hanspeter Spek |
Corporate headquarters Paris, Ile-de-france |
.
